On April 17 and 18, Critical Path Institute’s Clinical Outcome Assessment (COA) Program hosted its Annual Meeting in Rockville, MD, with more than 230 attendees, including 33 from the FDA.
The annual meeting included engaging sessions on using digital health technology to measure clinical outcomes and to allow patients to track their own personal treatment journey, using COAs for trial entry and stratification, mitigating challenges with multiple respondents, and multistakeholder perspectives on the value of patient-reported outcome data. The Electronic COA Consortium, Patient-Reported Outcome Consortium, and Rare Disease COA Consortium also provided updates on progress over the past year and the impacts their tools are having on the drug development landscape.
The annual meeting also included a 75-minute session comprised entirely of FDA panelists representing COA, biostatistics, neuroscience, patient-focused drug development, and medical devices where they provided clarity on topics encountered by sponsors and reviewers. Feedback is pouring in commending the quality of the event and the value of the information shared across the sessions. Materials from the sessions, including copies of slides and audio recordings, will be posted to C-Path’s website by the end of May.
